ERBB2 and breast cancer: Recently, the NeuVaxTM vaccine (developed by Galena Biopharma, a US-based biotechnology company), which is administered with Leukine® for the disease condition of BC with intermediate to low HER2 expression, was granted a Special Protocol Assessment for its Phase 3 trial (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer) [182].